News articles about Emergent Biosolutions (NYSE:EBS) have been trending somewhat positive recently, Accern Sentiment reports. The research firm rates the sentiment of news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Emergent Biosolutions earned a daily sentiment score of 0.16 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 46.6174823260529 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Here are some of the media stories that may have impacted Accern Sentiment’s rankings:

How to Become a New Pot Stock Millionaire

Emergent Biosolutions (NYSE EBS) opened at $50.95 on Thursday. The firm has a market cap of $2,500.00, a PE ratio of 31.26, a P/E/G ratio of 0.99 and a beta of 1.26. Emergent Biosolutions has a 12 month low of $27.94 and a 12 month high of $51.25. The company has a quick ratio of 3.42, a current ratio of 4.85 and a debt-to-equity ratio of 0.01.

Emergent Biosolutions (NYSE:EBS) last issued its quarterly earnings results on Thursday, February 22nd. The biopharmaceutical company reported $0.74 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.70 by $0.04. Emergent Biosolutions had a net margin of 14.73% and a return on equity of 13.66%. The firm had revenue of $193.80 million for the quarter, compared to analyst estimates of $189.96 million. During the same period last year, the company posted $0.74 EPS. Emergent Biosolutions’s quarterly revenue was up 27.8% compared to the same quarter last year. equities analysts anticipate that Emergent Biosolutions will post 2.33 earnings per share for the current fiscal year.

EBS has been the topic of several analyst reports. ValuEngine raised Emergent Biosolutions from a “hold” rating to a “buy” rating in a research report on Thursday, March 1st. Singular Research increased their price target on Emergent Biosolutions from $45.00 to $60.00 and gave the stock a “buy” rating in a research report on Tuesday, February 27th. Chardan Capital raised their target price on Emergent Biosolutions from $47.00 to $53.00 and gave the company a “buy” rating in a research report on Tuesday, January 16th. Zacks Investment Research cut Emergent Biosolutions from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, December 19th. Finally, Goldman Sachs Group started coverage on Emergent Biosolutions in a research report on Wednesday, January 24th. They set a “neutral” rating and a $55.00 target price on the stock. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $52.80.

In other Emergent Biosolutions news, EVP Adam Havey sold 1,898 shares of the firm’s stock in a transaction that occurred on Thursday, March 1st. The shares were sold at an average price of $49.50, for a total value of $93,951.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Jerome M. Hauer sold 5,152 shares of the firm’s stock in a transaction that occurred on Monday, January 22nd. The stock was sold at an average price of $50.91, for a total transaction of $262,288.32. Following the completion of the transaction, the director now directly owns 23,797 shares in the company, valued at $1,211,505.27. The disclosure for this sale can be found here. Insiders sold a total of 72,637 shares of company stock worth $3,391,674 over the last three months. Corporate insiders own 16.50% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Emergent Biosolutions (EBS) Getting Somewhat Positive Media Coverage, Study Finds” was originally posted by Marea Informative and is the property of of Marea Informative. If you are viewing this article on another site, it was illegally copied and republished in violation of United States & international copyright laws. The correct version of this article can be read at

About Emergent Biosolutions

Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).

Insider Buying and Selling by Quarter for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with's FREE daily email newsletter.